NCCN Guidelines® Insights: Thyroid Carcinoma, Version 1.2025.
作者信息
Haddad Robert I, Bischoff Lindsay, Applewhite Megan, Bernet Victor, Blomain Erik, Brito Maria, Busaidy Naifa Lamki, Campbell Michael, DeLozier Olivia, Duh Quan-Yang, Ehya Hormoz, Grady Erin, Guo Theresa, Haymart Megan, Hunt Jason P, Kandeel Fouad, Kotwal Anupam, Lamonica Dominick M, Lorch Jochen, Mandel Susan J, Markovina Stephanie, Mydlarz Wojciech, Nabell Lisle, Raeburn Christopher D, Rezaee Rod, Ridge John A, Ritter Hadley, Roth Mara Y, Salgado Sarimar Agosto, Scheri Randall P, Shah Jatin P, Sipos Jennifer A, Sippel Rebecca, Sturgeon Cord, Wirth Lori J, Wong Richard J, Worden Francis, Yeh Michael W, Darlow Susan, Cassara Carly J, Sliker Bailee
机构信息
1Dana-Farber/Brigham and Women's Cancer Center | Mass General Cancer Center.
2Vanderbilt-Ingram Cancer Center.
出版信息
J Natl Compr Canc Netw. 2025 Jul;23(7). doi: 10.6004/jnccn.2025.0033.
The NCCN Guidelines for Thyroid Carcinoma address the management of different types of thyroid carcinoma, including papillary, follicular, oncocytic, medullary, and anaplastic carcinoma. The NCCN Thyroid Carcinoma Panel meets at least annually to review comments from reviewers within their institutions, examine relevant new data from publications and abstracts, and reevaluate and update their recommendations. These NCCN Guidelines Insights focus on the panel's most recent recommendations regarding systemic therapies for thyroid carcinoma as well as the supporting clinical data.
Zotero 插件